Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2015 / Mar / A new ERA for IVF?
Biochemistry and molecular biology Genetics and epigenetics Omics Molecular Pathology

A new ERA for IVF?

By Roisin McGuigan 03/30/2015 1 min read

Share

Molecular testing of an endometrial biopsy could help fertility specialists choose the perfect time for embryo implantation

In the UK, just under a quarter of in vitro fertilization (IVF) treatments lead to live births, and this figure can vary dramatically by country, and even by clinic. Implantation failure, when the embryo cannot adhere to the endometrial lining is an influencing factor. Now, clinical trials are underway to validate a new molecular test that could identify the optimum time for embryo transfer and potentially increase IVF success rates: the endometrial receptivity array, or ERA.

0315-204-main

Juan Garcia-Velasco, Director of the Madrid fertility clinic IVI, and part of an international team of researchers studying ERA, told The Guardian (1), “We think that about 15 percent of cases of implantation failure are simply due to bad timing.” For most women, the crucial time during which implantation is likely to succeed can last for only a few days and is governed by a complex range of hormones and genetic factors. The current standard for assessing the status of the womb lining is with ultrasound, but this only provides visual information.

ERA could deliver previously unknown molecular information to fertility specialists. The test involves taking a small endometrial biopsy, then analyzing gene expression to predict the receptivity of the womb lining. In a pilot study of 85 women with a history of failed IVF treatment, researchers analyzed the activity of 238 genes expressed during different stages of the fertility cycle to create a transcriptomic profile, which was then coupled with a computational predictor of receptivity. In this preliminary study, the implantation rate using ERA was 33 percent (2). A larger clinical trial involving 2,500 women in over ten countries, including Spain and the UK, is now underway. “I think it will make a significant difference to the expectations of couples and how we can explain failures,” said Garcia-Velasco. “Until now, the endometrium was kind of a black box. Now we can say this was the problem and this is what we can do about it.”

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. The Guardian, “IVF test improves chances of implantation by pinpointing fertility window”, (2015). Available at: http://bit.ly/1wTiupK. Accessed 11 March 2015. M Ruiz-Alonso et al., “The endometrial receptivity array for diagnosis and personalized embryo transfer as a treatment for patients with repeated implantation failure”, Fertil Steril, 100, 818–824 (2013). PMID: 23756099.

About the Author(s)

Roisin McGuigan

I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as an Associate Editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.

More Articles by Roisin McGuigan

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Turning Tides
Biochemistry and molecular biology
Turning Tides

January 9, 2024

3 min read

A new study shows evidence for sustained human-to-human transmission of mpox since 2016

Molecular Spectacular
Biochemistry and molecular biology
Molecular Spectacular

January 8, 2024

1 min read

A look at last year’s most interesting molecular pathology stories

qPCR Infectious Disease Detective
Biochemistry and molecular biology
qPCR: Infectious Disease Detective

January 4, 2024

3 min read

How quantitative polymerase chain reaction really hits the mark in epidemic control and ID detection

Case of the Month
Biochemistry and molecular biology
Case of the Month

January 11, 2022

1 min read

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.